Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to supercharge weight loss

NCT ID NCT06862791

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether two experimental drugs, AZD9550 and AZD6234, given together as weekly shots, help people with obesity or overweight lose more weight than a placebo or either drug alone. 377 adults aged 18-75 with a BMI of 27 or higher and at least one weight-related health issue took part. The main goal was to see how much weight they lost after 36 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AZD9550 and AZD6234 (two experimental drugs given as weekly injections)
What this could lead to
If successful, this combination could offer a new, more effective weight-loss option for people with obesity or overweight.
What could go wrong
This is a Phase 2 trial, so it is still early. The combination may not prove better than existing treatments, and side effects are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

377 people

The number who actually took part.

Started

Feb 2025

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must be 18 to 75 years of age inclusive. * BMI: ≥ 30 kg/m2, or ≥ 27 kg/m2 with at least one weight related comorbidity. * A stable, self-reported body weight for 3 months prior to screening. * Male and female participants: Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * Female participants must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline. * Capable of giving signed informed consent. Exclusion Criteria: * History of any clinically important disease or disorder, which, in the opinion of the Investigator, may put the participant at risk. * History or presence of GI, renal, hepatic disease. * Previous or planned bariatric surgery or fitting of a weight loss device. * Obesity induced by endocrine disorders such as Cushing's syndrome, insulinoma or Prader-Willi syndrome. * History of T1DM or T2DM or symptoms indicative of insulinopenia or poor glucose control. * HbA1c ≥ 6.5% (48 mmol/mol), fasting serum glucose ≥ 126 mg/dL (7.0 mmol/L) or random glucose ≥ 200 mg/dL (11.1 mmol/L). * Significant gastric and hepatobiliary disease. * History of acute or chronic pancreatitis or pancreatic amylase or lipase \> 2 × ULN at screening. * History of psychosis or bipolar disorder. * History of major depressive disorder within the 2 years prior to screening or depression. * Treatment with a GLP1 containing preparation, either as part of treatment or while participating in another clinical study within the 3 months or 5 half-lives of the drug prior to screening. * Vulnerable populations

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity or overweight

Contacts and locations

Locations

  • Research Site

    Dothan, Alabama, 36305, United States

  • Research Site

    Vestavia Hills, Alabama, 35216, United States

  • Research Site

    Cerritos, California, 90703, United States

  • Research Site

    Escondido, California, 92025, United States

  • Research Site

    Huntington Park, California, 90255, United States

  • Research Site

    Lincoln, California, 95648, United States

  • Research Site

    Sacramento, California, 95864, United States

  • Research Site

    Waterbury, Connecticut, 06708, United States

  • Research Site

    Palm Harbor, Florida, 34684, United States

  • Research Site

    Decatur, Georgia, 30030, United States

  • Research Site

    Stockbridge, Georgia, 30281, United States

  • Research Site

    Champaign, Illinois, 61822, United States

  • Research Site

    South Bend, Indiana, 46617, United States

  • Research Site

    Valparaiso, Indiana, 46383, United States

  • Research Site

    Sioux City, Iowa, 51106, United States

  • Research Site

    Southfield, Michigan, 48034, United States

  • Research Site

    Missoula, Montana, 59804, United States

  • Research Site

    Omaha, Nebraska, 68114, United States

  • Research Site

    Albuquerque, New Mexico, 87107, United States

  • Research Site

    Fargo, North Dakota, 58104, United States

  • Research Site

    Cincinnati, Ohio, 45219, United States

  • Research Site

    Columbus, Ohio, 43213, United States

  • Research Site

    Tulsa, Oklahoma, 74133, United States

  • Research Site

    Medford, Oregon, 97504, United States

  • Research Site

    Kingsport, Tennessee, 37660, United States

  • Research Site

    Brownsville, Texas, 78526, United States

  • Research Site

    Houston, Texas, 77043, United States

  • Research Site

    Arlington, Virginia, 22206, United States

  • Research Site

    Renton, Washington, 98057, United States

  • Research Site

    Maroochydore, 4556, Australia

  • Research Site

    Maroubra, 2035, Australia

  • Research Site

    Norwood, 5067, Australia

  • Research Site

    St Albans, 3021, Australia

  • Research Site

    St Leonards, 2065, Australia

  • Research Site

    Calgary, Alberta, T2V 4J2, Canada

  • Research Site

    Surrey, British Columbia, V3T 4G8, Canada

  • Research Site

    Guelph, Ontario, N1G 0B4, Canada

  • Research Site

    Hamilton, Ontario, L8J 0B6, Canada

  • Research Site

    Hamilton, Ontario, L8L 5G8, Canada

  • Research Site

    Sarnia, Ontario, N7T 4X3, Canada

  • Research Site

    Stouffville, Ontario, L4A1H2, Canada

  • Research Site

    Montreal, Quebec, H4N 2W2, Canada

  • Research Site

    Berlin, 10787, Germany

  • Research Site

    Essen, 45136, Germany

  • Research Site

    Falkensee, 14612, Germany

  • Research Site

    Hamburg, 22607, Germany

  • Research Site

    Münster, 48145, Germany

  • Research Site

    Oldenburg, 23758, Germany

  • Research Site

    Chūōku, 103-0027, Japan

  • Research Site

    Chūōku, 104-0031, Japan

  • Research Site

    Fukuoka, 812-0025, Japan

  • Research Site

    Shinjuku-ku, 160-0008, Japan

  • Research Site

    Suita-shi, 565-0853, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.